DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Conditions: HER2 Breast Cancer; Non-small Cell Lung Carcinoma Interventions: Drug: Trastuzumab deruxtecan (DS-8201a); Drug: Pembrolizumab Sponsors: Daiichi Sankyo, Inc.; AstraZeneca UK Limited; Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Non-Small Cell Lung Cancer | Research